Nuvation Bio启动Safusidenib治疗IDH1突变胶质瘤的关键全球III期Sigma试验(G203)

美股速递
Feb 09

Nuvation Bio公司正式宣布,针对其创新药物Safusidenib在IDH1突变型胶质瘤治疗领域的关键性全球III期Sigma临床试验(代号G203)已全面启动。这一里程碑式的进展标志着该疗法向商业化迈出决定性一步,为神经肿瘤领域带来新的治疗希望。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10